IPO Databook: TRex Bio (TRXB US) - Oct 2026

84 Views07 Oct 2026 10:18

SUMMARY

TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for immunoregulatory medicines to restore immune balance and promote tissue repair.
The company has TRB-061 in Phase 1a/b for atopic dermatitis, TRB-071 in IND-enabling studies, and TRB-051 in Phase 2a via a Lilly collaboration.
The company reported collaboration revenue of $39,108 thousand for FY2024, but also a net loss of $(29,308) thousand for six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream